William Blair & Company
FOLD

William Blair & Company’s Amicus Therapeutics FOLD Stock Holding History

William Blair & Company’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60,266
Closed -$644K – 1840
2024
Q3 		$644K Buy
60,266
+13,012
+28% +$142K ﹤0.01% 1048
2024
Q2 		$469K Buy
47,254
+6,237
+15% +$64K ﹤0.01% 1115
2024
Q1 		$483K Buy
41,017
+102
+0.2% +$1.3K ﹤0.01% 1095
2023
Q4 		$581K Buy
40,915
+5,461
+15% +$62K ﹤0.01% 1035
2023
Q3 		$431K Buy
+35,454
New +$457K ﹤0.01% 1101

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair & Company's FOLD Position: Q4 2024 in Review

William Blair & Company sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 60,266 shares — an estimated $644K sold.

William Blair & Company first reported a position in FOLD in Q3 2023 and held it in 5 quarters. The position peaked at $644K in Q3 2024. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • William Blair & Company reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • William Blair & Company sold 60,266 Amicus Therapeutics shares in Q4 2024, an estimated $644K.
  • William Blair & Company first reported a position in Amicus Therapeutics in Q3 2023 and held it in 5 quarters.
  • William Blair & Company's Amicus Therapeutics position peaked at $644K in Q3 2024.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on William Blair & Company's 13F filing for Q4 2024, filed 12 Feb 2025.